Approval · Notice of Compliance 37374 · 2026
REMODULIN: Notice of Compliance 37374
Issued April 21, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37374
- Date
- April 21, 2026
- Company
- United Therapeutics CorporationDurham, North Carolina, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Product Monograph reformatted to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REMODULIN | Not yet assigned | — |
Medicinal ingredients
- TREPROSTINIL SODIUM 1 MG per ML
- TREPROSTINIL SODIUM 2.5 MG per ML
- TREPROSTINIL SODIUM 5 MG per ML
- TREPROSTINIL SODIUM 10 MG per ML